<qa>  What is the name of the study that was used in the early phase II?An early phase II, single arm, two stage study, to investigate the level of activity, duration of response and tolerability of brentuximab vedotin SGN-35, as a single agent, utilising a response adapted approach, in older, frailer or co-morbid patients with previously untreated Hodgkin lymphoma. 